Amgen Inc. $AMGN Stock Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN) by 88.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 75,992 shares of the medical research company’s stock after purchasing an additional 35,730 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Amgen were worth $32,031,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. MW Advisory LLC acquired a new stake in Amgen during the second quarter worth $1,054,000. Baird Financial Group Inc. raised its position in Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after purchasing an additional 5,496 shares during the period. KBC Group NV raised its position in Amgen by 51.7% in the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock valued at $138,574,000 after purchasing an additional 130,497 shares during the period. Nilsine Partners LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $3,329,000. Finally, Integrated Advisors Network LLC lifted its stake in shares of Amgen by 50.5% in the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after purchasing an additional 6,356 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last 90 days. Company insiders own 0.85% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire delivered strong Phase 3 results. Amgen and AstraZeneca reported that Tezspire produced statistically significant improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. Reuters reported a 69% remission rate, strengthening the case for a potential expansion of Tezspire beyond asthma. Reuters Tezspire Phase 3 results
• Positive Sentiment: Analysts remain bullish. Piper Sandler maintained a Buy rating and set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s pipeline, earnings outlook and portfolio diversification. Piper Sandler Amgen rating
• Positive Sentiment: Recent financial performance supports the growth narrative. Amgen’s latest quarterly results exceeded expectations, with earnings per share of $6.29 versus the $5.62 consensus and revenue of $10.05 billion versus $9.43 billion expected. Revenue increased 9.5% year over year, helping reinforce the investment story. Amgen earnings beat analysis
• Neutral Sentiment: Additional catalysts are approaching. Amgen plans to present oncology data and other research at the European Society for Medical Oncology Congress on October 24, which could provide further pipeline updates. Amgen ESMO 2026 presentation
• Negative Sentiment: Valuation and execution risks remain. Amgen trades at a considerably higher valuation than Bristol Myers Squibb, according to comparative coverage, leaving less room for disappointment. Tezspire’s opportunity also depends on regulatory approval and successful commercialization in EoE. Amgen versus Bristol Myers Squibb comparison

Amgen Price Performance

AMGN opened at $438.34 on Thursday. The stock’s 50-day moving average price is $416.63 and its 200 day moving average price is $376.69. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $236.98 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 3.21 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research analyst reports. Cantor Fitzgerald increased their price target on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a report on Monday, October 5th. Argus boosted their price objective on shares of Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Morgan Stanley reduced their price objective on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 7th. Sanford C. Bernstein upped their target price on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Finally, Wells Fargo & Company lowered their target price on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research note on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $388.64.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.